Higher macular volume in patients with MS receiving fingolimod: positive outcome or side effect?

Tools

Item Type:	Editorial
Title:	Higher macular volume in patients with MS receiving fingolimod: positive outcome or side effect?
Creators Name:	Dinkin, M. and Paul, F.
Abstract:	In the evaluation of patients with multiple sclerosis (MS), optical coherence tomography (OCT) is gaining traction as a tool to assess thinning of the retinal nerve fiber layer (RNFL) and, more recently, for looking at total macular volume (TMV) thickness, with both measures used as potential biomarkers for progression of disease. In medicine, it is not uncommon for structural changes to be presumed to reflect a certain physiologic process, when in fact an alternative mechanism is at play. Fingolimod (FTY-720) is a sphingosine-1-phosphate receptor modulator that is an approved oral treatment for MS and leads to reduced cortical volume loss in patients with MS.(1) Similar to other disease-modifying agents, it is likely to be judged in part by its ability to slow loss of the RNFL and TMV. But would such a judgment be valid?
Keywords:	Fingolimod Hydrochloride, Immunosuppressive Agents, Macula Lutea, Multiple Sclerosis, Propylene Glycols, Sphingosine
Source:	Neurology
ISSN:	0028-3878
Publisher:	American Academy of Neurology
Volume:	80
Number:	2
Page Range:	128-129
Date:	8 January 2013
Official Publication:	https://doi.org/10.1212/WNL.0b013e31827ccf4a
PubMed:	View item in PubMed

Repository Staff Only: item control page